A. Favaretto

发表

Mitomycin C, vinblastine, and carboplatin regimen in patients with nonsmall cell lung cancer: A phase II trial

M. Fiorentino, A. Paccagnella, A. Morabito, 1996, Cancer.

Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial.

U. Dafni, R. Stahel, S. Peters, 2017, The Lancet. Respiratory medicine.

A Clinical-Genetic Score to Identify Surgically Resected Colorectal Cancer Patients Benefiting From an Adjuvant Fluoropyrimidine-Based Therapy

M. Montico, L. Quartuccio, S. De Vita, 2018, Front. Pharmacol..

Elderly Patients with Small Cell Lung Cancer

A. Paccagnella, F. Oniga, R. Biason, 2002, Tumori.

Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland

A. Goldhirsch, S. Gelber, A. Partridge, 2022, Journal of Cancer Survivorship.

Clinical profile and mortality of Sars-Cov-2 infection in cancer patients across two pandemic time periods (Feb 2020–Sep 2020; Sep 2020–May 2021) in the Veneto Oncology Network: The ROVID study

M. Dieci, V. Chiarion-Sileni, V. Zagonel, 2022, European Journal of Cancer.

A Pilot Study of Concomitant Radiation and Chemotherapy in Patients with Locally Advanced Head and Neck Cancer

A. Paccagnella, V. Chiarion-Sileni, L. Tomio, 1993, American journal of clinical oncology.

The Genotype for DPYD Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice

F. Innocenti, M. Berretta, J. Polesel, 2018, Clinical pharmacology and therapeutics.

Paclitaxel and carboplatin in combination with gemcitabine: a phase I-II trial in patients with advanced non-small-cell lung cancer. Gruppo Studio Tumori Polmonari Veneto (GSTPV).

G. Ceresoli, A. Paccagnella, E. Villa, 2000, Annals of oncology : official journal of the European Society for Medical Oncology.

Role of Genotyping in Non-Small Cell Lung Cancer Treatment

M. Rugge, R. Rosell, M. Taron, 2011, Drugs.

Cisplatin, etoposide, and ifosfamide in non‐small cell lung carcinoma. A phase II randomized study with cisplatin and etoposide as the control arm

A. Brandes, A. Paccagnella, V. Chiarion-Sileni, 1990, Cancer.

Cisplatin versus carboplatin in combination with mitomycin and vinblastine in advanced non small cell lung cancer. A multicenter, randomized phase III trial.

G. Ceresoli, V. Chiarion Sileni, A. Paccagnella, 2004, Lung cancer.

Adding gemcitabine to paclitaxel/carboplatin combination increases survival in advanced non-small-cell lung cancer: results of a phase II-III study.

A. Chella, M. Clerici, G. Ceresoli, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Carboplatin and paclitaxel plus avelumab compared with carboplatin and paclitaxel in advanced or recurrent endometrial cancer (MITO END-3): a multicentre, open-label, randomised, controlled, phase 2 trial.

M. Nicoloso, S. Pignata, G. de Matteis, 2023, The Lancet. Oncology.

Platinum-etoposide chemotherapy in elderly patients with small-cell lung cancer: results of a randomized multicenter phase II study assessing attenuated-dose or full-dose with lenograstim prophylaxis--a Forza Operativa Nazionale Italiana Carcinoma Polmonare and Gruppo Studio Tumori Polmonari Veneto

C. Tibaldi, A. Ardizzoni, L. Boni, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second and third responses to the same induction regimen in relapsing patients with multiple myeloma

A. Paccagnella, V. Chiarion-Sileni, D. Casara, 1991, Cancer.

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

M. Pirmohamed, A. Cambon-Thomsen, Yitian Zhou, 2023, The Lancet.

Pre-operative chemoradiotherapy in non-small cell lung cancer stage III patients. Feasibility, toxicity and long-term results of a phase II study.

A. Paccagnella, V. Chiarion-Sileni, F. Rea, 1996, European journal of cancer.

Granulocyte‐macrophage colony‐stimulating factor increases dose intensity of chemotherapy in small cell lung cancer: Relationship between clinical results, peripheral blood cell modifications, and bone marrow kinetics

A. Paccagnella, L. Chieco‐Bianchi, A. Riccardi, 1993, Cancer.

82 Treatment of small cell lung cancer (SCLC) in elderly patients (E.P.)

A. Paccagnella, A. Morabito, L. Tomio, 1995 .

HLA-G 3′UTR Polymorphisms Predict Drug-Induced G3-4 Toxicity Related to Folinic Acid/5-Fluorouracil/Oxaliplatin (FOLFOX4) Chemotherapy in Non-Metastatic Colorectal Cancer

J. Polesel, A. Buonadonna, G. Toffoli, 2017, International journal of molecular sciences.

Negative prognostic factors and resulting clinical outcome in patients with metastatic renal cell carcinoma included in the Italian nivolumab-expanded access program.

C. Porta, F. di Costanzo, S. Buti, 2018, Future oncology.

Pemetrexed plus carboplatin in elderly patients with malignant pleural mesothelioma: combined analysis of two phase II trials

V. Torri, F. Cappuzzo, A. Ceribelli, 2008, British Journal of Cancer.

Long term results of surgery and chemotherapy in small cell lung cancer.

A. Paccagnella, F. Rea, A. Favaretto, 1998, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery.

Concomitant Drugs Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Receiving Ipilimumab and Nivolumab in the Compassionate Use Program in Italy: Brief Communication

C. Porta, S. Buti, M. Bersanelli, 2022, Journal of immunotherapy.

Prognostic factors in elderly patients with malignant pleural mesothelioma: results of a multicenter survey

G. Ceresoli, M. Mencoboni, F. Grosso, 2014, British Journal of Cancer.

Full dose (FD) chemotherapy (CT) plus lenograstim and low dose (LD) CT in elderly SCLC patients. A phase II randomized fonicap-GSTPV study

A. Ardizzoni, L. Boni, A. Paccagnella, 2000 .

Extramedullary plasmacytoma: clinical behaviour and response to treatment.

A. Paccagnella, V. Chiarion-Sileni, A. Favaretto, 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase II study of pemetrexed and carboplatin plus bevacizumab as first-line therapy in malignant pleural mesothelioma

G. Ceresoli, M. Mencoboni, L. Gianoncelli, 2013, British Journal of Cancer.

Paclitaxel and carboplatin in combination with gemcitabine (PCG): A phase I–II trial in advanced non-small cell lung cancer (NSCLC)

G. Ceresoli, A. Paccagnella, F. Barbieri, 1998 .

Employment trajectories of young women with breast cancer: an ongoing prospective cohort study in Italy and Switzerland

A. Goldhirsch, S. Gelber, A. Partridge, 2022, Journal of Cancer Survivorship.